- Proteomics International Laboratories (PIQ) signs a deal with medical diagnostics company Apacor to bring its PromarketD test to Britain
- PromarkerD is a biomarker-based blood test that predicts kidney function decline in type 2 diabetes
- The two-year distribution agreement gives Apacor the license to sell the immunoassay version of the PromarkerD test
- Through the deal, Proteomics will receive payment for each PromarkerD kit sold and will begin once PromarkerD is available on the UK market
- Proteomics International last traded at 90 cents on November 22
Proteomics International Laboratories (PIQ) has signed a deal to expand its distribution network into Britain.
The company signed a two-year agreement with medical diagnostics company Apacor to bring its PromarketD test for diabetic kidney disease to patients in England, Scotland and Wales.
“After extensive due diligence, we identified Apacor as a great partner for PromarkerD in Britain – they are well connected and we are already in contact with key bodies and opinion leaders to promote the test and bring PromarkerD into the clinic,” Proteomics International managing director, Dr Richard Lipscombe said.
PromarkerD is a biomarker-based blood test that predicts kidney function decline in type 2 diabetes. Diabetic kidney disease is a major complication arising from diabetes, with PromarkerD the only test currently available for predicting the onset of the disease.
The company said early diagnosis of diabetic kidney disease can help inform doctors’ treatment decisions to improve clinical outcomes for patients and would save costs for the health care system by reducing progression of the disease.
“The easy-to-use PromarkerD immunoassay platform allows hundreds of blood samples to be analysed quickly as part of a panel of routine blood tests and we expect this UK distribution deal to further drive global demand for the test,” said Dr Lipscombe.
The distribution agreement gives Apacor the license to sell the immunoassay version of the PromarkerD test.
Through the deal, Proteomics will receive payment for each PromarkerD kit sold.
The agreement will officially begin on the date PromarkerD is available on the UK market – which Proteomics anticipated will be within the next two months. This date is conditional on product registration with the UK’s Medicines and Healthcare Products Regulatory Agency.
PromarkerD is already CE Mark registered in the European Union until 30 June 2023, before which the company said it will apply for a UK Conformity Assessed mark.
Proteomics International last traded at 90 cents on November 22.